PTO/SB/088 (07-05)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

JUN 13 2006 ons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Red Substitute for form 1449/PTO

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

1

Sheet

(Use as many sheets as necessary) of

Complete if Known					
Application Number	10/698,928				
Filing Date	October 31, 2003				
First Named Inventor	Serge H. Boyer				
Art Unit	1626				
Examiner Name	Taofiq A. Solola				
Attorney Docket Number	2358.0180002/RWE/AES				

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T²
NPL1	SARTILLO-PISCIL, F., et al., "Fosfato-ésteres ciclicos diastereoisoméricos: 5-bromo-4-fenil-2-fenoxi-2-oxo-1,3,2-dioxafosforinanos, precursores de radicales libres alquilo β-fosfatoxi y generadores de radicales catiónicos en medio no oxidativo," Rev. Soc. Quim. Mexico 46:330-334, Journal of the Mexican Chemical Society (December 2002)	
NPL2	English Translation of SARTILLO-PISCIL, F., et al., "Cyclic diastereoisomeric phosphate esters: 5-bromo-4-phenyl-2-phenoxy-2-oxo-1,3,2-dioxaphosphorinanes, free β-(phosphatoxy) alkyl radical precursors and cation radical generators in non-oxidative medium," Rev. Soc. Quim. Mexico 46:330-334, Journal of the Mexican Chemical Society (December 2002)	
NPL3	TAKAKU, H., et al., "Synthesis of Deoxyribooligonucleotides Using Cesium Fluoride by the Phosphotriester Approach," Nippon Kagaku Kaishi (no. 10):1968-1973, The Chemical Society of Japan, Inc. (1985)	
NPL4	English translation of TAKAKU, H., et al., "Synthesis of Deoxyribooligonucleotides Using Cesium Fluoride by the Phosphotriester Approach," Nippon Kagaku Kaishi (no. 10):1968-1973, The Chemical Society of Japan, Inc. (1985)	
NPL5	THUONG, NT. and Chabrier, P., "Nouvelle méthode de préparation de la phosphorylcholine, de la phosphorylhomocholine et de leurs dérivés," <i>Bull. Soc. Chim. France 1-2</i> :667-671, Masson and Co. (1974)	
NPL6	English translation of THUONG, N.T. and Chabrier, P., "New Method for Preparation of Phosphoryl choline, of phosphoryl homocholine and their derivatives," <i>Bull. Soc. Chim. France 1-2</i> :667-671, Masson and Co. (1974)	
NPL7	Dialog File 351, Accession No. 11683821, WPI English language abstract of WO 97/49717	
NPL8	Copy of Office Action for U.S. Application No. 11/145,194, Mark D. Erion et al., filed June 3, 2005, mailed March 24, 2006	
		Yes
• • • • • • • • • • • • • • • • • • • •	No. ' NPL1 NPL2 NPL3 NPL4 NPL5 NPL6 NPL7	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published SARTILLO-PISCIL, F., et al., "Fosfato-ésteres cíclicos diastereoisoméricos: 5-bromo-4-fenil-2-fenoxi-2-oxo-1,3,2-dioxafosforinanos, precursores de radicales libres alquilo β-fosfatoxi y generadores de radicales catiónicos en medio no oxidativo," Rev. Soc. Quim. Mexico 46:330-334, Journal of the Mexican Chemical Society (December 2002) English Translation of SARTILLO-PISCIL, F., et al., "Cyclic diastereoisomeric phosphate esters: 5-bromo-4-phenyl-2-phenoxy-2-oxo-1,3,2-dioxaphosphorinanes, free β-(phosphatoxy) alkyl radical precursors and cation radical generators in non-oxidative medium," Rev. Soc. Quim. Mexico 46:330-334, Journal of the Mexican Chemical Society (December 2002) NPL3

544158.1

Examiner Signature	· A. 50/0/a	Date Considered	7-27-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivatent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Pape work Reduction Act of Tello no persons are required to respond to a collection of information unless it contains a valid OMB control number.

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURES
STATEMENT BY APPLATOR

(Use as many sheets as necessary)

of

 Complete if Known

 Application Number
 10/698,928

 Filing Date
 October 31, 2003

 First Named Inventor
 Serge H. Boyer

 Art Unit
 1626

 Examiner Name
 Taofiq A. Solola

 Attorney Docket Number
 2358.0180002/RWE/AES

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,
initiais	INO.	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
YO	US1	6,946,115	09/20/2005	Erion et al.	
	US2	3,328,388	06/27/1967	Shen et al.	
	US3	2002/0120130 A1	08/29/2002	Gosselin et al.	
<u> </u>	US4	2005/0101776 A1	05/12/2005	Gosselin et al.	
	 				
					
	ļ				
					
	<u> </u>		<u> </u>	L	

		Fo	REIGN PATENT DO	OCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code' Number' Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
					or Relevant Figures Appear	T⁵
10	FP1	NL6511420	03/03/1966	Merck & Co., Inc.		
	FP2	WO 95/07287 A1	03/16/1995	Centre National de la Recherche Scientifique		
	FP3	WO 97/49717 A1	12/31/1997	Fedorov, I.I. et al.		Abs
						<u> </u>
						
						

544157_1.DOC

Sheet

Examiner Signature T. A. Sololy Date Considered 7-27-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.' Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 t and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Un	der the Papers	work Redu	ction Act of 1995, no pers	ons are required a RADIO a collection of i	nformation unless it contains a valid OMB control number		
Substitute for form 1449/PTO FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE				Complete if Known			
			CNITAT	Application Number	10/698,928		
				Filing Date	October 31, 2003		
				First Named Inventor	Serge H. Boyer		
			PLICANT	Art Unit	1626		
(Use as many sheets as necessary)		Examiner Name	Taofiq A. Solola				
Sheet	1	of	1	Attorney Docket Number	2358.0180002/RWE/AES (MTI-046)		

			-
	, 	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T²
10	C1	BOYER, S. et al., "The Discovery of MB07133: A HepDirect® Prodrug of Cytarabine Monophosphate for the Treatment of Hepatocellular Carcinoma," poster presentation at the American Chemical Society (ACS) Prospective, Boston, MA (May 2006).	
	C2	ERION, M. et al., "HepDirect Prodrugs for Targeting Nucleotide-Based Antiviral Drugs to the Liver", Current Opinion in Investigational Drugs 7(2): 109-117, The Thomson Corporation (2006).	
	СЗ	MA, B, et al., "A Phase I/II Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MB07133 in Subjects with Unresectable Hepatocellular Carcinoma (HCC) (Poster ID 2054, no. 19)," poster presentation at the American Society of Clinical Oncology (ASCO) Conference, Atlanta, Georgia (June 2006).	

Examiner Date 7-30-06 Signature Considered

561024.1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Red stion Act of 1995, no s are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(050 45		cis us necessary,	
1	of	1	

Complete if Known				
Application Number	10/698,928			
Filing Date	October 31, 2003			
First Named Inventor	Serge H. Boyer			
Art Unit	1626			
Examiner Name	Taofiq A. Solola			
Attorney Docket Number	2358.0180002/RWE/AES (MTI-046)			

				U.S. PATENT DO	CUMENTS	
	Examiner Initials	Cite No.1		Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines,
IIIIIIa	13	140.	Number-Kind Code ^{2 (If Known)}	MIM-DD-1111	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
7	0	A1	5,854,231	12-29-1998	Camden	
	<u> </u>	A2	6,037,335	03-14-2000	Takashima et al.	
						
				 		
				<u> </u>		
<u> </u>						
ļ						

			FOREIGN PATE	ENT DOCUMENTS		
Examiner Initials*	Cite No.		Publication Date	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Country Code Number Kind Code (if known)	MM-DD- YYYY	Document	Figures Appear	T⁴
70	B1	WO 95/07920	03-23-1995	Gilead Sciences	·	
	<u> </u>					

561023.1

Examiner Signature	T.A.	Solo Car	Date Considered	7-30-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and In soliection of information is required by 37 CPR 1.97 and 1.96. The information is required to obtain or retain a perient by the public which is to like to her to by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Page 150. Box 1450. Alexandria, VA 22313-1450.